Baxter buys Chatham Therapeutics

Written By Sun-Times Wire Posted: 04/02/2014, 10:16am

Sign-up for Chicago Sun-Times newsletters.

Baxter International Inc. has acquired Chatham Therapeutics LLC, a company working on treatments for hemophilia.

Deerfield-based Baxter will make an initial $70 million payment for Chatham, with any future payments based on achieving development, regulatory and commercial goals.

“Chatham’s gene therapy platform technology offers the potential to redefine treatment of both hemophilia A and B,” said Ludwig Hantson, president of Baxter BioScience. “This technology will be highly complementary to our expanding pipeline of bleeding disorder treatments as we continue our pursuit of a bleed-free world.”

Baxter and Chatham in May 2012 began collaborating on a treatment for hemophilia B.

ALSO: Baxter splitting into 2 separate businesses

ALSO: Baxter to increase heart drug production

Browse More 'News'